Katcher Arielle H, Greenman Michelle P, Roychoudhury Sudarshana, Goldberg Gary L
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, New Hyde Park, NY, United States.
Division of Gynecologic Oncology, Christiana Care Health System, Newark, DE, United States.
Gynecol Oncol Rep. 2024 Nov 29;56:101550. doi: 10.1016/j.gore.2024.101550. eCollection 2024 Dec.
The use of immunohistochemistry (IHC) and molecular pathology has been widely adopted over the past 3 decades and has aided in the precision of diagnosing gynecologic tumors. While many tumors can be diagnosed by histologic appearance on routine hematoxylin and eosin stained slides, the use of IHC has dramatically changed practice, leading to a better understanding and subtyping of gynecologic tumors. This detailed classification of tumors has aided in the implementation and development of targeted therapies. Available IHC stains and their applications continue to rapidly evolve. Our review aims to provide updated information on the use of IHC in gynecologic tumors. We will also address the rationale for preferred therapeutic regimens that are personalized based on IHC.
在过去三十年中，免疫组织化学（IHC）和分子病理学的应用已被广泛采用，并有助于提高妇科肿瘤诊断的准确性。虽然许多肿瘤可以通过常规苏木精和伊红染色切片的组织学外观进行诊断，但免疫组织化学的应用极大地改变了实践，使人们对妇科肿瘤有了更好的理解和亚型分类。这种详细的肿瘤分类有助于靶向治疗的实施和发展。现有的免疫组织化学染色及其应用仍在迅速发展。我们的综述旨在提供有关免疫组织化学在妇科肿瘤中应用的最新信息。我们还将阐述基于免疫组织化学的个性化首选治疗方案的基本原理。
